Mahkam Zanganeh bought $411k of SMMT
Chief Executive Officer at Summit Therapeutics Inc.. 110,321 shares at an average of $3.73, traded Mar 26, 2024, filed Mar 27, 2024.
Score components
- +25RoleCEO
- +16Trade size$411k at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +4Price context26% below the 52-week high
- +8Cluster2 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (2 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +2.9%, 3m +107.2%, 6m +503.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001599298-24-000047, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Mar 27, 2024 | POpen-market purchase Common Stock | +26,000 | $3.72 | $97k | 520,814 | Mar 27, 2024 |
| Mar 27, 2024 | POpen-market purchase Common Stockindirect: By the Mahkam Zanganeh Revocable Trust, with the Reporting Person as Trustee | +34,321 | $3.72 | $128k | 24,923,800 | Mar 27, 2024 |
| Mar 26, 2024 | POpen-market purchase Common Stockindirect: Immediate family member | +30,000 | $3.75 | $113k | 30,000 | Mar 27, 2024 |
| Mar 27, 2024 | POpen-market purchase Common Stockindirect: Immediate family member | +20,000 | $3.71 | $74k | 50,000 | Mar 27, 2024 |
Related signals
Other insiders at Summit Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 78Notable | Summit Therapeutics Inc. | Robert W Duggan Co-Chief Executive Officer | $50M 3,810,000 shares | +1% | |
| 83Strong | Summit Therapeutics Inc. | Mahkam Zanganeh Co-Chief Executive Officer | $50M 3,810,000 shares | +1% | |
| 73Notable | Summit Therapeutics Inc. | Robert W Duggan Co-Chief Executive Officer | $1.5M 100,000 shares | +0% | |
| 76Notable | Summit Therapeutics Inc. | Manmeet Singh Soni COO and CFO | $722k 50,000 shares | +2% | |
| 78Notable | Summit Therapeutics Inc. | Mahkam Zanganeh Co-Chief Executive Officer | $1.5M 100,000 shares | +0% | |
| 73Notable | Summit Therapeutics Inc. | Robert W Duggan Co-Chief Executive Officer | $500k 26,680 shares | +53% | |
| 73Notable | Summit Therapeutics Inc. | Mahkam Zanganeh Co-Chief Executive Officer | $500k 26,680 shares | +53% | |
| 55Moderate | Summit Therapeutics Inc. | Yu Xia director | $10.0M 533,617 shares | +2% | |
| 53Moderate | Summit Therapeutics Inc. | Robert W Duggan Co-Chief Executive Officer | $6.0M 338,394 shares | +0% | |
| 53Moderate | Summit Therapeutics Inc. | Mahkam Zanganeh Co-Chief Executive Officer | $6.0M 338,394 shares | +0% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.